Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Retinopathy of Prematurity > Postnatal steroids in preterm infants associated with severity of retinopathy of prematurity
  • Retinopathy of Prematurity

Postnatal steroids in preterm infants associated with severity of retinopathy of prematurity

Ophthalmology 360

Cumulative dose and duration of postnatal steroid use are independently associated with the severity of retinopathy of prematurity (ROP) and the development of peripheral avascular retina (PAR) in preterm infants, according to a study.

 Of the 1695 infants born at ≤32 weeks gestation and/or with a birth weight ≤1500 g included in this study, 67% received postnatal steroid treatment. The infants had an average birth weight of 1142 ± 396 g and gestational age of 28.6 ± 2.7 weeks. The mean cumulative dose of steroids prescribed was 28.5 ± 74.3 mg/kg, and the average duration of treatment was 8.9 ± 35.1 days.

After accounting for major demographic differences, the researchers found a significant association between higher cumulative doses and longer durations of steroid therapy and an increased incidence of severe ROP and PAR (P < 0.001). For each additional day of steroid treatment, there was a 3.2% increase in the hazard of developing the severe form of ROP (95% CI: 1.022-1.043). Moreover, the time required to achieve full retinal vascularization was delayed by 5.7% (95% CI: 1.04-1.08) for each day of steroid treatment (P < 0.001).

Reference
Shekhawat PS, Ali MAM, Kannekanti N, et al. Impact of postnatal steroids on peripheral avascular retina and severity of retinopathy of prematurity. Pediatr Res. 2023;doi: 10.1038/s41390-023-02673-4. Epub ahead of print. PMID: 37291231.

Share

Related Content

  • Dry Eye

Analysis of FDA reports reveals widespread ocular adverse events linked to antidepressants

  • Cornea and External Disease

Phase 3 trial of cenegermin-bkbj for PCED enrolls first US patient

  • Retina Care 360

Physical activity shows mixed effects on visual outcomes in type 2 diabetes

  • Trending Topics

AI-based diagnostics show promise for early ocular disease detection

  • Trending Topics

Study explores retinal findings in pregnant women with COVID-19

  • Trending Topics

Spotlight on VYZULTA®

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon